The rapid development of multiple vaccines providing strong protection from severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a major achievement …

Over the past year, numerous studies in the peer reviewed and preprint literature have
reported on the virological, epidemiological and clinical characteristics of the coronavirus …

T cell responses play an important role in protection against beta-coronavirus infections,
including SARS-CoV-2, where they associate with decreased COVID-19 disease severity …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the
COVID-19 pandemic. Neutralizing Abs target the receptor binding domain of the spike (S) …

SARS-CoV-2 infection causes respiratory insufficiency and neurological manifestations,
including loss of smell and psychiatric disorders, and can be fatal. Most vaccines are based …

SARS-CoV-2 nucleocapsid protein (N) induces strong antibody (Ab) and T cell responses.
Although considered to be localized in the cytosol, we readily detect N on the surface of live …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein is the
main antigen in all approved COVID-19 vaccines and is also the only target for monoclonal …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs)
possess mutations that confer resistance to neutralizing antibodies within the Spike protein …

The emergence of SARS-CoV-2 variants of concern (VOC) is driven by mutations that
mediate escape from neutralizing antibodies. There is also evidence that mutations can …

While first-generation, spike (S)-based COVID-19 vaccines were effective against early
SARS-CoV-2 strains, the rapid evolution of novel Omicron subvariants have substantially …